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Received November 12, 2015; accepted April 18, 2016AbstractBackground: Among patients with very small vessel disease and chronic kidney disease (CKD), the comparative efficacy of bare metal stents
(BMSs) versus drug-eluting stents (DESs) is not frequently addressed. This study aimed to evaluate the long-term outcomes of patients with very
small vessel disease managed with percutaneous coronary intervention.
Methods: Our study included 158 consecutive patients undergoing percutaneous coronary intervention from January 2003 to December 2013.
The primary end points were cardiovascular death and target vessel failure, which consisted of cardiovascular death, target vessel-related
myocardial infarction, and ischemia-driven target vessel revascularization.
Results: BMSs were used in 37 patients, while DESs were utilized in 121 patients. During the mean follow-up period of 2.7 ± 2.2 years (median
2.1 years; interquartile range, 1.34.2 years), the target vessel failure rate was 48.6% versus 28.1% (BMS vs. DES, p ¼ 0.020) and the car-
diovascular death rate was 27% versus 18.2% (BMS vs. DES, p ¼ 0.241). The use of a DES (hazard ratio: 0.44, 95% confidence interval:
0.24e0.79, p ¼ 0.006) remained the most significant predictor of target vessel failure after multivariate analysis. In CKD subgroup analysis, the
benefit of a 2.25 mm DES was evident only in the subgroup with CKD, but such a benefit disappeared in those without CKD.
Conclusion: Compared with BMSs, implantation of DESs in a patient population with very small vessel disease effectively reduced target vessel
failure. However, the beneficial effects of DESs appeared to be evident only in the subgroup with CKD.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Previous studies have shown that patients with small ves-
sels are at a higher risk of restenosis and adverse outcomes
after percutaneous coronary intervention (PCI).1e4 The use of
drug-eluting stents (DESs) has been demonstrated to be
effective in reducing not only the risk of restenosis, but also
the incidence of repeated revascularization, compared with
bare metal stents (BMSs).5e15 Ardissino et al16 reported thatsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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restenosis and major adverse cardiac events (MACEs) in small
vessels with a diameter of  2.75 mm when compared with a
BMS. Furthermore, an SES is associated with a lower rate of
clinical and angiographic restenosis when compared with a
paclitaxel-eluting stent, although the rates of death, myocar-
dial infarction (MI), and stent thrombosis were similar for both
stents,17e19 and such a benefit was also observed in the non-
diabetes mellitus subgroup.20 By contrast, patients with very
small coronary vessel (2.25 mm) disease are less frequently
included in these clinical trials, and the long-term prognosis
(> 1 year) of stenting with a DES or BMS remains unclear.
Therefore, the aim of our study was to evaluate the long-term
clinical outcomes of patients with very small vessel disease
who were treated with 2.25 mm stents.
2. Methods
This study included 158 consecutive patients undergoing
PCI with stenting for very small vessels ( 2.25 mm) in Taipei
Veterans General Hospital, Taipei, Taiwan from January 2003
to December 2013. The vessel size was determined by quan-
titative coronary analysis in the catheterization laboratory.2.1. Interventional procedureWe performed PCI and ventriculography using the standard
procedure, after obtaining signed informed consent from all
patients. Unfractionated heparin (10,000 IU bolus) was
administered prior to the procedure to achieve an activated
clotting time of > 300 seconds. After predilatation, we
deployed the stent with high-pressure balloon dilatation to
achieve optimal stent apposition. Debulking by means of
rotablator was used only in highly calcified lesions, and the use
of intravascular ultrasound and glycoprotein IIb/IIIa receptor
antagonist was at the operators’ discretion. Coronary stenting
was considered angiographically successful if residual stenosis
< 30% with coronary thrombolysis in myocardial infarction
Grade 3 flow was obtained at the end of the procedure. After
stent implantation, all patients received aspirin (100 mg/d)
indefinitely and clopidogrel (300 mg loading dose, then 75 mg/
d) or ticlopidine (500 mg loading dose, then 250 mg twice a
day) for at least 1 month (BMS) or at least 12 months (DES).
Medications for the treatment of angina pectoris (calcium
channel blockers, beta-blockers, and nitrates) were continued.2.2. Angiographic analysisCoronary angiograms were obtained after intracoronary
injection of nitroglycerin. Quantitative coronary angiographic
end points included reference vessel diameter, minimum
lumen diameter (MLD), percent diameter stenosis (% DS),
acute gain, and late lumen loss. Acute gain was defined as the
difference between the MLD immediately after the placement
of the stent and the MLD before the procedure. Late lumen
loss was defined as the difference between the MLD imme-
diately after the procedure and the MLD at follow-up.Reference vessel diameter, MLD, and % DS were measured
before the procedure and at follow-up.2.3. Follow-upThe clinical follow-up data were collected by scheduled
monthly clinic evaluations or through direct telephone contact.
All patients were followed up completely, without any noted
case loss during follow-up.2.4. Primary end pointThe primary end point of the study included cardiovascular
death and target vessel failure (TVF), which included car-
diovascular death, target-vessel-related MI, and ischemia-
driven target vessel revascularization. Cardiovascular death
was defined as death related to a cardiovascular diagnosis,
complications of procedure, or unexplained (unexpected)
causes. MI was defined as the presence of significant new Q
waves in at least two electrocardiographic leads or symptoms
compatible with MI associated with an increase in creatine
kinase-MB fraction more than three times the upper limit of
the reference range. Target lesion revascularization was
defined as any repeated percutaneous intervention of the target
lesion performed for > 50% angiographic renarrowing of the
treated lesion from 5 mm proximal to 5 mm distal to the stent,
or repeat bypass surgery. Stent thrombosis occurrence was
classified as definite, probable, or possible according to the
Academic Research Consortium criteria,21 and was considered
as acute (within 24 hours), subacute (within 30 days), late
(after 30 days and within 12 months), and very late (after 1
year). As chronic kidney disease (CKD) might be associated
with clinical outcomes of these patients with small stents, we
calculated the estimated glomerular filtration rate according to
the simplified version of the Modification of Diet in Renal
Disease Study prediction equation formula, modified by Ma
et al22 for Chinese patients [estimated glomerular filtration
rate ¼ 175  plasma creatinine1.234  age0.179  0.79 (if
female)]. Chronic kidney disease was defined as estimated
glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 for 
3 months . The study protocol was approved by the Institu-
tional Review Board at Taipei Veterans General Hospital, and
informed written consent was obtained from each participant.2.5. Statistical analysisContinuous data are presented as the mean ± standard de-
viation or with a confidence interval (CI) of 95%. Categorical
variables were compared by Chi-square test or Fisher’s exact
test. Continuous variables are presented as mean ± standard
deviation and were compared by Student t test. Baseline
characteristics and clinical outcomes were compared between
patients treated with BMSs versus those treated with DESs in
each group. The long-term actuarial event-free survival curve
of patients undergoing PCI was estimated by the use of the
KaplaneMeier method. Cox regression analysis was per-
formed to determine independent predictors of primary end
Table 1
Baseline patient characteristics of patients with different type of stent (BMS
and DES).
Baseline demographics BMS (n ¼ 37) DES (n ¼ 121) p
N % N %
Age (y) 72.7 ± 10.8 72.5 ± 12.2 0.255
Gender (%) 0.228
Male 30 81.1 86 71.1
Female 7 18.9 35 28.9
Lab data
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with p < 0.10 in the univariate analysis being included in the
stepwise multivariate model. The hazard ratio (HR) and 95%
CI were calculated. A p value < 0.05 was considered to be
statistically significant. The software package SPSS version
20.0 (SPSS Inc., Chicago, IL, USA) was used for statistical
analysis.
3. ResultsCreatinine 2.1 ± 2.3 1.9 ± 2.1 0.989
eGFR 52.3 ± 26.3 58.0 ± 29.5 0.2933.1. Patient characteristics
LVEF 45.5 ± 14.6 47.8 ± 12.1 0.107
Procedure characteristics (%)
Stent length (mm) 21.9 ± 5.1 25.1 ± 5.8 0.006
Calcification 16 43.2 56 46.3 0.745
Bifurcation 0 0 4 3.3 0.263
CTO 18 48.6 50 41.3 0.431
IVUS 5 13.5 23 19 0.444
Rotablation 2 5.4 13 10.7 0.326
IABP 4 10.8 10 8.3 0.633
ECMO 2 5.4 3 2.5 0.374
Cardiogenic shock 5 13.5 9 7.4 0.255
PCI due to ACS 16 43.2 42 34.7 0.346
Unstable angina 3 8.1 11 9.1 0.854
STEMI 5 13.5 6 5.0 0.074
NSTEMI 9 24.3 23 19.0 0.481
VT/Vf 1 2.7 11 9.1 0.199
IIb/IIIa 4 10.8 17 14 0.612
Treated vessel (%)
RCA 6 16.2 18 14.9 0.842
LAD 16 43.2 61 50.4 0.445
LCX 14 37.8 40 33.1 0.592
RI 1 2.7 2 1.7 0.682
Comorbidities (%)
CHF 14 37.8 33 27.3 0.219
Previous CABG 2 5.4 15 12.4 0.230
Previous PCI 12 32.4 46 38.0 0.537
Previous MI 4 10.8 21 17.4 0.340
Previous CVA 8 21.6 12 9.9 0.061
PAOD 6 16.2 11 9.1 0.221
Hypertension 35 94.6 107 88.4 0.277
Diabetes mellitus 20 54.1 73 60.3 0.497The baseline characteristics of the 158 patients are sum-
marized in Table 1. The mean age of the population was
72.6 ± 11.9 years, with male (73.4%) predominance. About
one-third of the patients presented with acute coronary syn-
drome (53 patients, 33%). In particular, 93 (58.8%) patients
and 78 (49.4%) patients suffered from diabetes and CKD,
respectively, suggesting that our patients belonged to the high-
risk population. All patients were successfully treated with
PCI, with 121 patients (76.4%) receiving DESs and 37
receiving BMSs (23.6%). In the DES group, first-generation
stents (SESs and paclitaxel-eluting stents) were used in 25
patients, and new-generation DESs, including everolimus-
eluting and zotarolimus-eluting stents, were used in 92 pa-
tients. There were no significant differences in procedure
characteristics between the two groups except that the stent
length was significantly longer in the DES group
(21.9 ± 5.1 mm in the BMS group, 25.1 ± 5.8 mm in the DES
group, p ¼ 0.006). Of note, the use of small stents in the
chronic total occlusion lesion was similar in both groups [10
(27%) in the BMS group, and 47 (38.8%) in the DES group,
p ¼ 0.190]. Furthermore, the use of rotablation and intravas-
cular ultrasound was also similar in both groups [1 (2.7%)
patient and 5 (13.5%) patients in the BMS group, 13 (10.7%)
patients and 23 (19%) patients in the DES group, p ¼ 0.132
and p ¼ 0.444, respectively].CKD 21 56.8 57 47.1 0.304
Hyperlipidemia 26 70.6 81 66.9 0.705
Smoking 13 35.1 35 28.9 0.472
3.2. Angiographic resultsMultivessel 33 89.2 114 94.2 0.293
Data are presented as mean ± standard deviation or n (%).
ACS ¼ acute coronary syndrome; BMS¼ bare metal stent; CABG ¼ coronary
artery bypass graft surgery; CHF ¼ congestive heart failure; CKD ¼ chronic
kidney disease; CTO ¼ chronic total occlusion; CVA ¼ cerebral vascular
accident; DES ¼ drug-eluting stent; ECMO ¼ extracorporeal membrane
oxygenation; eGFR ¼ estimated glomerular filtration rate; IABP ¼ intra-aortic
balloon pumping; IVUS ¼ intravascular ultrasound; LAD ¼ left anterior
descending artery; LCX ¼ left circumflex artery; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; NSTEMI ¼ non-ST segment
elevation myocardial infarction; PAOD ¼ peripheral arterial occlusive disease;
PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery;Acute and follow-up angiographic results were comparable
between the DES and BMS groups, as shown in Table 2.
Compared with the BMS group, the reference vessel diameter
and lesion length before procedure were, respectively, smaller
and longer in the DES group (1.96 ± 0.31 mm vs.
2.07 ± 0.19 mm, p ¼ 0.013 and 24.73 ± 5.90 mm vs.
22.45 ± 5.02, p ¼ 0.049, respectively). At follow-up, the use
of DESs was associated with significantly less % DS and less
late loss (% DS: 10.01 ± 22.39 vs. 47.64 ± 41.17, p ¼ 0.005;
late loss: 0.24 ± 0.51 vs. 1.14 ± 0.96, p ¼ 0.004).RI ¼ ramus intermediate; STEMI ¼ ST segment elevation myocardial
infarction; Vf ¼ ventricular fibrillation; VT ¼ ventricular tachycardia.3.3. OutcomesThe mean follow-up period was 2.7 ± 2.2 years (median,
2.1 years; interquartile range, 1.34.2 years). The adverse
events during the follow-up period are summarized in Table 3,
and there were 32 cardiovascular deaths [10 (27%) in the BMSgroup, 22 (18.2%) in the DES group, p ¼ 0.241] and 52 TVF
[18 (48.6%) in the BMS group, 34 (28.1%) in the DES group,
p ¼ 0.02]. One case of subacute stent thrombosis was noted in
the BMS group 24 days after index procedure, which resulted
Table 2
Quantitative coronary angiography results.
QCA in-stent lesion characteristics BMS (n ¼ 37) DES (n ¼ 121) p
Before intervention
RVD (mm) 2.07 ± 0.19 1.96 ± 0.31 0.013
MLD (mm) 0.11 ± 0.15 0.12 ± 0.16 0.748
% DS 94.62 ± 7.19 93.58 ± 9.23 0.559
Lesion length (mm) 22.45 ± 5.02 24.73 ± 5.90 0.049
After intervention
Acute gain (mm)a 2.20 ± 0.16 2.15 ± 0.18 0.204
Follow-up
RVD (mm) 2.15 ± 0.32 2.24 ± 0.14 0.211
MLD (mm) 1.16 ± 0.98 2.05 ± 0.53 0.004
% DS 47.64 ± 41.17 10.01 ± 22.39 0.005
Late lumen loss (mm)b 1.14 ± 0.96 0.24 ± 0.51 0.004
Data are presented as means ± standard deviation.
BMS ¼ bare metal stent; DES ¼ drug-eluting stent; DS ¼ diameter stenosis;
MLD ¼ minimal luminal diameter; QCA ¼ quantitative coronary angiog-
raphy; RVD ¼ reference vessel diameter.
a Acute gain was defined as the difference between the minimal luminal
diameter immediately after and before the placement of the stent.
b Late lumen loss was defined as the difference between the minimal luminal
diameter immediately after the procedure and the minimal luminal diameter
during follow-up.
Fig. 1. KaplaneMeier analysis for the probability of cumulative survival free
from target vessel failure according to the use of BMSs and DESs.
BMS ¼ bare metal stent; DES ¼ drug-eluting stent; TVF ¼ target vessel
failure.
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late stent thrombosis. Fig. 1 shows the cumulative incidence
curves of TVF obtained by the use of the KaplaneMeier
method between the BMS and DES groups, and also shows
that the use of a DES was associated with a lower risk of TVF
( p < 0.001). In multivariate Cox regression analysis, the use of
DES (HR: 0.44, 95% CI: 0.24e0.79, p ¼ 0.006), clinical
presentation as acute coronary syndrome (HR: 2.48, 95% CI:
1.41e4.37, p ¼ 0.002), and left ventricular ejection fraction
(HR: 0.94, 95% CI: 0.93e0.96, p < 0.001) were identified as
independent predictors of TVF. By contrast, creatinine upon
admission (HR: 1.18, 95% CI: 1.06e1.32, p ¼ 0.002), disease
presented as acute coronary syndrome (HR: 3.23, 95% CI:
1.52e6.87, p ¼ 0.002), and left ventricular ejection fraction
(HR: 0.95, 95% CI: 0.92e0.97, p < 0.001) were independent
predictors of cardiovascular death (Table 4). Moreover, sub-
group analysis showed that the use of DESs was associated
with a lower risk of TVF than BMSs only in patients withTable 3
Outcomes of patients with different types of stents (BMSs and DESs).
Outcomes BMS (n ¼ 37) DES
(n ¼ 121)
p
N % N %
MACCE 18 48.6 35 28.9 0.026
MI 3 8.0 3 2.5 0.117
Stroke 3 8.0 3 2.5 0.117
All-cause mortality 13 35.1 30 24.8 0.216
TLR 8 21.6 11 9.1 0.040
TVF 18 48.6 34 28.1 0.020
CV death 10 27.0 22 18.2 0.241
BMS ¼ bare metal stent; CV ¼ cardiovascular; DES ¼ drug-eluting stent;
MACCE ¼ major adverse cardiac and cerebrovascular event;
MI ¼ myocardial infarction; TLR ¼ target lesion revascularization;
TVF ¼ target vessel failure.CKD ( p  0.01), but not in patients without CKD ( p ¼ 0.61;
Fig. 2). There was a significant interaction between the pre-
dictive power of the use of DESs/BMSs for TVF risk and CKD
(interaction p ¼ 0.01). By contrast, the use of first- or new-
generation DESs in patients with or without diabetes did not
appear to be associated with the risk of long-term TVF or
cardiovascular death.
As a 2.25 mm stent might be used either alone or in
connection with a larger stent for full-metal jacket stenting, we
compared the results of the 2.25 mm stent alone (n ¼ 117) or
as a part of long stenting (n ¼ 41), and found that there were
no significant differences in TVF and cardiovascular death
between these two groups ( p ¼ 0.564 and p ¼ 0.052,
respectively).
4. Discussion
The results of this study showed that in a high-risk cohort
undergoing coronary stenting for very small coronary artery,
the use of DESs was associated with fewer incidents of TVF
compared with the use of BMSs. In particular, the beneficial
effect of 2.25 mm DESs appeared to be evident only in pa-
tients with CKD, but not in those without CKD.
Few studies have compared the clinical safety and efficacy
of DESs and BMSs for the treatment of very small vessel (<
2.5 mm) disease. The post hoc subanalysis of TAXUS V trialTable 4
Analyses of risk factors for target vessel failure (cardiovascular death, target
vessel-related myocardial infarction, target vessel revascularization) and car-
diovascular death in all groups (BMS and DES).
Predictive variables Target vessel failure Cardiovascular death
HR (95% CI) p HR (95% CI) p
Cr when admission d d 1.18 (1.06e1.32) 0.002
ACS 2.48 (1.41e4.37) 0.002 3.23 (1.52e6.87) 0.002
LVEF 0.94 (0.93e0.96) <0.001 0.95 (0.92e0.97) <0.001
Drug-eluting stent 0.44 (0.24e0.79) 0.006 d d
ACS ¼ acute coronary syndrome; BMS ¼ bare metal stent; CI ¼ confidence
interval; Cr ¼ creatinine; DES ¼ drug-eluting stent; HR ¼ hazard ratio;
LVEF ¼ left ventricular ejection fraction.
Fig. 2. KaplaneMeier analysis for the probability of cumulative survival free
from target vessel failure according to the (A) absence or (B) presence of
CKD. BMS ¼ bare metal stent; CKD ¼ chronic kidney disease; DES ¼ drug-
eluting stent; TVF ¼ target vessel failure.
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diameter of 2.08 mm treated with 2.25 mm paclitaxel-eluting
stents. This showed that restenosis rates were reduced signif-
icantly when compared with BMSs, although angiographic
binary restenosis and target lesion revascularization still
occurred in approximately 20% and 10% of patients, respec-
tively, using DESs. Furthermore, in this subanalysis, there
were no significant differences in the rates of death, MI, and
stent thrombosis at 1 month and 9 months between the
paclitaxel-eluting stent and BMS groups.23 Another subgroup
analysis from the RESEARCH Registry by Lemos et al24
compared the performance of 2.25 mm SESs with that of
SESs of  2.5 mm diameter in the same procedure. At the 1-
year follow-up, the binary restenosis rate and target lesion
revascularization were 10.7% and 5.5%, respectively.25 Our
study also showed similar results that the use of DESs was
associated with lower risk of TVF and cardiac vascular death.However, the rate of TVF was much higher in our study, which
may be related to more comorbidities in our population.
Further studies for very small vessel stenting in a lower-risk
cohort are recommended.
Few trials have examined the association between stent
efficacy and clinical outcomes in patients with CKD arising
from concerns of higher MACE rates, mortality, higher prev-
alence of diabetes mellitus,26 lower procedure success rate,
coronary lesion calcification and lesion complexity,27e32
greater thrombogenicity,33,34 increased platelet dysfunction,
and risk of restenosis.35,36 Previous reports had compared first-
generation DESs with BMSs, and revealed that the use of
DESs may decrease the risk of target vessel revascularization;
however, DES use was not effective in reducing mortality risk
in CKD patients.24,37,38 Ishio et al39 also reported that SESs,
compared with BMSs, reduced in-stent restenosis but not in-
segment restenosis or target lesion revascularization in pa-
tients on dialysis (mean stent diameter, 3.03 ± 0.36 mm).
Furthermore, Toutouzas et al40 found that second-generation
DESs (mean stent diameter, 2.92 ± 0.32 mm) had increased
efficacy and were safe in reducing the rates of target lesion
revascularization and stent thrombosis compared with those in
non-CKD patients, although no significant differences
regarding MACEs or nonfatal MI were found.
When first- and second-generation DESs were compared,
Chan et al41 reported that in patients with creatinine clearance
< 60 mL/min, the use of first- and second-generation DESs
showed a similar rate of nonfatal MI, target vessel revascu-
larization, and all-cause mortality, with the only noted supe-
riority for second-generation DESs over BMSs being 4-year
MACEs.42e44 Thereafter, patients with CKD appear to be at
high risk for long-term MACE compared with patients without
CKD. The use of DESs in patients with CKD may reduce the
risk of instent restenosis (ISR) and target vessel revasculari-
zation. However, the very small vessel disease in the CKD
subgroup had never been investigated. Our result supported the
proposition that superiority of 2.25 mm DESs over BMSs is
evident only in patients with CKD.4.1. LimitationsSeveral limitations of the present study should be
acknowledged, which included its small sample size, non-
randomized nature, and different stenting times because
treatment strategies to address very small vessel disease have
evolved over time. Moreover, being a single-center observa-
tional retrospective analysis, there is an inherent selection bias,
an under-reporting bias, and confounding factors related to
unmeasured variables; these results should be confirmed in a
prospective randomized manner. Third, only about two-thirds
of our patients received follow-up coronary angiography by
clinical indications (102 patients, 64.5%), and incomplete
angiographic follow-up-related potential bias might have a
substantial impact on the analytic results.
In conclusion, DESs were associated with a lower risk of
TVF when compared with BMSs in patients treated for very
small vessel (< 2.25 mm) disease. However, these beneficial
647W.-T. Wang et al. / Journal of the Chinese Medical Association 79 (2016) 642e648effects of DESs appeared to be evident only in the subgroup
with CKD.
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